Sugammadex Dosing in Newborns

Introduction to Sugammadex Use in Newborns

The American Society of Anesthesiologists recommends that sugammadex is not used in newborns due to insufficient safety and efficacy data in this population 1, 2

As of 2018, sugammadex had not yet been granted marketing approval for children under 2 years of age, making its use in a newborn off-label and not supported by current guidelines 1, 2

Neostigmine 0.04-0.05 mg/kg combined with atropine 0.02 mg/kg is the standard approach for reversal of rocuronium-induced neuromuscular blockade in newborns 3, 4
Administer neostigmine and atropine only when at least 4 responses to train-of-four (TOF) stimulation are present 3
Expect reversal to TOF ratio ≥0.9 in 10-20 minutes 3
Quantitative neuromuscular monitoring is essential in pediatric patients, as residual neuromuscular blockade occurs in 28% of children receiving muscle relaxants 1, 5

For rapid sequence induction in newborns, succinylcholine 1.8 mg/kg is the first-line muscle relaxant (GRADE 1+) 1, 6, 5
Rocuronium >0.9 mg/kg is the alternative when succinylcholine is contraindicated 1, 6, 5
The duration of apnea without hypoxemia is significantly shorter in newborns, necessitating rapid airway protection 1, 5

Never use succinylcholine in newborns with neuromuscular diseases due to risk of rhabdomyolysis or life-threatening hyperkalemia 1, 5
Muscle relaxants during inhaled induction in infants have documented benefits for intubation conditions and reduced respiratory events 1, 5
The allergic risk with muscle relaxants in pediatric populations is low but incompletely characterized 1, 5

In obese patients, sugammadex dosing is adjusted to ideal body weight rather than actual body weight, demonstrating that simple weight-based dosing is not universally applicable 7, 8, 9